Výsledky vyhledávání - "D. B. Rodgers"

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis

Autor: G.-Y. Genti, C. Amante, B. Sarembock, C. T. Chow, C. A. F. Zerbini, S. L. Chen, F. Vrijens, M. Laurenzi, R. Myllykangas-Luosujärvi, D. B. Rodgers, G. Pasero, H. S. Lu, L. De Tora, D.S.K. Choon, A. Moan

Publikováno v: Scandinavian Journal of Rheumatology. 31:337-344

Objective : To compare the efficacy and safety of rofecoxib 12.5 mg once daily to naproxen 500 mg twice daily in patients S 40 years of age with knee or hip osteoarthritis (OA). Methods : Two identical 6-week, randomized, double-blind studies were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fa967180ed2673e6b9b40020159c246
https://doi.org/10.1080/030097402320817059

Zobrazit plný text záznamu

Tolerability profiles of rofecoxib (Vioxx®) and Arthrotec®: A comparison of six weeks treatment in patients with osteoarthritis

Autor: A. D. Beaulieu, N. Casas, S. Gutierrez-Urena, M. Laurenzi, M. Ugaz, Eduardo Acevedo, Bernardo A. Pons-Estel, F. Irazoque, D. B. Rodgers, K. Vandormael, W. Hinojosa, O. Castaneda, Francisco Caeiro, Mario Alberto Garza-Elizondo

Publikováno v: Scandinavian Journal of Rheumatology. 30:19-24

To compare the incidence of selected spontaneously reported adverse events (AEs) in patients with osteoarthritis (OA) treated with rofecoxib (VIOXX, 12.5 mg qd) or Arthrotec (diclofenac 50 mg/misoprostol 200 mcg bid).Double-blind, parallel-group, 6-w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7890425a3a328f27b8378af6a8c40cf
https://doi.org/10.1080/030097401750065274

Zobrazit plný text záznamu

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration

Autor: R, Myllykangas-Luosujärvi, H S, Lu, S L, Chen, D, Choon, C, Amante, C T, Chow, G, Pasero, Gy, Genti, B, Sarembock, C A F, Zerbini, F, Vrijens, A, Moan, D B, Rodgers, L, De Tora, M, Laurenzi

Publikováno v: Scandinavian journal of rheumatology. 31(6)

To compare the efficacy and safety of rofecoxib 12.5 mg once daily to naproxen 500 mg twice daily in patientsor = 40 years of age with knee or hip osteoarthritis (OA).Two identical 6-week, randomized, double-blind studies were conducted (1 in Africa,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::56683d95b6e7c0e945c8207b165d1aec
https://pubmed.ncbi.nlm.nih.gov/12492248

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání